Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease

被引:1
|
作者
Li, Sha [1 ]
Liu, Hui-Hui [1 ]
Guo, Yuan-Lin [1 ]
Zhu, Cheng-Gang [1 ]
Wu, Na-Qiong [1 ]
Xu, Rui-Xia [1 ]
Dong, Qian [1 ]
Qian, Jie [1 ]
Dou, Ke-Fei [1 ]
Li, Jian-Jun [1 ]
机构
[1] Chinese Acad Med Sci, FuWai Hosp, Peking Union Med Coll, Cardiometab Ctr,Natl Ctr Cardiovasc Dis,State Key, Beijing, Peoples R China
来源
关键词
ASCVD; risk stratification; Chinese; high-risk conditions; outcome; MYOCARDIAL-INFARCTION; AMERICAN-COLLEGE; CORONARY; ASSOCIATION; MANAGEMENT; IMPACT;
D O I
10.3389/fendo.2022.860698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and AimsHeterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. Current guidelines have definitely refined the disease and we aimed to examine the practicability in Chinese population. MethodsA cohort of 9944 patients with ASCVD was recruited. Recurrent events occurred during an average of 38.5 months' follow-up were collected. The respective and combinative roles of major ASCVD (mASCVD) events and high-risk conditions, being defined by 2018 AHA/ACC guideline, in coronary severity and outcome were studied. ResultsThe number of high-risk conditions was increased with increasing number of mASCVD events (1.95 +/- 1.08 vs. 2.16 +/- 1.10 vs. 2.42 +/- 1.22). Trends toward the higher to the highest frequency of multi-vessel coronary lesions were found in patients with 1- (71.1%) or >= 2 mASCVD events (82.8%) when compared to those without (67.9%) and in patients with 2- (70.5%) or >= 3 high-risk conditions (77.4%) when compared to those with 0-1 high-risk condition (61.9%). The survival rate was decreased by 6.2% between none- and >= 2 mASCVD events or by 3.5% between 0-1 and >= 3 high-risk conditions. Interestingly, diabetes was independently associated with outcome in patients with 1- [1.54(1.06-2.24)] and >= 2 mASCVD events [1.71(1.03-2.84)]. The positive predictive values were increased among groups with number of mASCVD event increasing (1.10 vs. 1.54 vs. 1.71). ConclusionPropitious refinement of ASCVD might be reasonable to improve the survival. Concomitant diabetes was differently associated with the incremental risk among different ASCVD categories, suggesting the need of an appropriate estimate rather than a 'blanket' approach in risk stratification.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] QUANTITATIVE PLAQUE STAGING SYSTEM PREDICTS LONG-TERM CARDIOVASCULAR OUTCOMES IN PATIENTS AT RISK FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Nurmohamed, Nick S.
    Bom, Michiel
    Jukema, Ruurt
    De Groot, Robin
    Driessen, Roel
    Van Diemen, Pepijn
    Sprengers, Ralf
    Min, James K.
    Earls, James P.
    Danad, Ibrahim
    Choi, Andrew D.
    Knaapen, Paul
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1153 - 1153
  • [22] Obesity and cardiovascular disease: From pathophysiology to risk stratification
    Marinou, Kyriakoula
    Tousoulis, Dimitris
    Antonopoulos, Alexios S.
    Stefanadi, Elli
    Stefanadis, Christodoulos
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 138 (01) : 3 - 8
  • [23] Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients
    Dai, Lingyan
    Jiang, Chunxiang
    Cui, Qingmei
    Huang, Leen
    Chen, Siqi
    Zhang, Yidan
    Luo, Xiaoyi
    Zhang, Piao
    Li, Jie
    Zhang, Yuhu
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2025, 12 (01):
  • [24] COHORT STUDY OF CARDIOVASCULAR RISK STRATIFICATION IN CHINESE
    Zhang Weizhong
    JOURNAL OF HYPERTENSION, 2018, 36 : E136 - E136
  • [25] Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease
    Yawen Jiang
    Weiyi Ni
    PharmacoEconomics, 2019, 37 : 943 - 952
  • [26] Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease
    Jiang, Yawen
    Ni, Weiyi
    PHARMACOECONOMICS, 2019, 37 (07) : 943 - 952
  • [27] Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia
    Mszar, Reed
    Bart, Sarah
    Sakers, Alexander
    Soffer, Daniel
    Karalis, Dean G.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [28] Atherosclerotic cardiovascular disease risk prediction: current state-of-the-art
    Rout, Amit
    Duhan, Sanchit
    Umer, Muhammad
    Li, Miranda
    Kalra, Dinesh
    HEART, 2024, 110 (15) : 1005 - 1014
  • [29] Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives
    Masson, Walter
    Fernandez-Villar, Gonzalo
    Martinez-Elhelou, Solange
    ADVANCES IN THERAPY, 2025, : 2118 - 2134
  • [30] Improving risk stratification for cardiovascular disease
    van Wijk, Diederik F.
    Boekholdt, S. Matthijs
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (08) : 1091 - 1093